Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Dinh, Minh H"'
Autor:
Pitiyarachchi, Omali, Ansell, Peter J., Coleman, Robert L., Dinh, Minh H., Holman, Laura, Leath, Charles A., III, Werner, Theresa, DiSilvestro, Paul, Morgan, Mark, Tew, William, Lee, Christine, Cunningham, Mary, Newton, Meredith, Edraki, Babak, Lim, Peter, Barlin, Joyce, Spirtos, Nicola M., Tewari, Krishnansu S., Edelson, Mitchell, Reid, Thomas, Carlson, Jay, Friedlander, Michael
Publikováno v:
In Gynecologic Oncology August 2024 187:221-226
Autor:
Linton, Kim M *, Vitolo, Umberto, Jurczak, Wojciech, Lugtenburg, Pieternella J, Gyan, Emmanuel, Sureda, Anna, Christensen, Jacob Haaber, Hess, Brian, Tilly, Hervé, Cordoba, Raul, Lewis, David John, Okada, Craig, Hutchings, Martin, Clausen, Michael Roost, Sancho, Juan-Manuel, Cochrane, Tara, Leppä, Sirpa, Chamuleau, Martine E D, Gernhardt, Diana, Altıntaş, Işıl, Liu, Yan, Ahmadi, Tahamtan, Dinh, Minh H, Hoehn, Daniela, Favaro, Elena, Elliott, Brian, Thieblemont, Catherine, Vose, Julie M
Publikováno v:
In The Lancet Haematology August 2024 11(8):e593-e605
Autor:
Clarke, Jeffrey M., Patel, Jyoti D., Robert, Francisco, Kio, Ebenezer A., Thara, Eddie, Ross Camidge, D., Dunbar, Martin, Nuthalapati, Silpa, Dinh, Minh H., Bach, Bruce A.
Publikováno v:
In Lung Cancer November 2021 161:180-188
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Aghajanian, Carol, Swisher, Elizabeth M., Okamoto, Aikou, Steffensen, Karina Dahl, Bookman, Michael A., Fleming, Gini F., Friedlander, Michael, Moore, Kathleen N., Tewari, Krishnansu S., O'Malley, David M., Chan, John K., Ratajczak, Christine, Hashiba, Hideyuki, Wu, Meijing, Dinh, Minh H., Coleman, Robert L.
Publikováno v:
Gynecologic oncology, vol 164, iss 2
Aghajanian, C, Swisher, E M, Okamoto, A, Steffensen, K D, Bookman, M A, Fleming, G F, Friedlander, M, Moore, K N, Tewari, K S, O'Malley, D M, Chan, J K, Ratajczak, C, Hashiba, H, Wu, M, Dinh, M H & Coleman, R L 2022, ' Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer : an ancillary data analysis of the VELIA trial ', Gynecologic Oncology, vol. 164, no. 2, pp. 278-287 . https://doi.org/10.1016/j.ygyno.2021.12.012
Aghajanian, C, Swisher, E M, Okamoto, A, Steffensen, K D, Bookman, M A, Fleming, G F, Friedlander, M, Moore, K N, Tewari, K S, O'Malley, D M, Chan, J K, Ratajczak, C, Hashiba, H, Wu, M, Dinh, M H & Coleman, R L 2022, ' Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer : an ancillary data analysis of the VELIA trial ', Gynecologic Oncology, vol. 164, no. 2, pp. 278-287 . https://doi.org/10.1016/j.ygyno.2021.12.012
ObjectiveIn the Phase 3 VELIA trial (NCT02470585), veliparib added to carboplatin plus paclitaxel concomitantly and as maintenance for women with newly-diagnosed advanced ovarian cancer significantly improved progression-free survival (PFS) versus ch
Autor:
Karimi, Yasmin H., Thieblemont, Catherine, Ghesquieres, Herve, Cheah, Chan Y., Roost Clausen, Michael, Cunningham, David, Jurczak, Wojciech, Linton, Kim M., Hutchings, Martin, Phillips, Tycel, Farooq, Umar, Seog Kim, Won, Dinh, Minh H., Ghosh, Jagannath, Pallai, Rajash, Wielgos-Bonvallet, Monica, Eskelund, Christian, Lugtenburg, Pieternella J., Vose, Julie M.
Publikováno v:
In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S461-S462
Autor:
Karimi, Yasmin H., Thieblemont, Catherine, Ghesquieres, Herve, Cheah, Chan Y., Roost Clausen, Michael, Cunningham, David, Jurczak, Wojciech, Linton, Kim M., Hutchings, Martin, Phillips, Tycel, Farooq, Umar, Seog Kim, Won, Dinh, Minh H., Ghosh, Jagannath, Pallai, Rajash, Wielgos-Bonvallet, Monica, Eskelund, Christian, Lugtenburg, Pieternella J., Vose, Julie M.
Publikováno v:
In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S212-S212
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Okamoto, Aikou, Fleming, Gini F, Bookman, Michael A, Brady, M.F., Swisher, Elizabeth M, Dahl Steffensen, Karina, Cloven, Noelle G, Enomoto, T, Dinh, Minh H, Coleman, Robert L, Aghajanian, Carol
Publikováno v:
Okamoto, A, Fleming, G F, Bookman, M A, Brady, M F, Swisher, E M, Dahl Steffensen, K, Cloven, N G, Enomoto, T, Dinh, M H, Coleman, R L & Aghajanian, C 2020, ' Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study ', Annals of Oncology, vol. 31, no. Suppl. 4, 818P, pp. S618 . https://doi.org/10.1016/j.annonc.2020.08.957
BackgroundThe phase III randomised VELIA study (NCT02470585) demonstrated significantly improved progression-free survival (PFS) with carboplatin/paclitaxel (CP) and veliparib (VEL) induction therapy followed by VEL maintenance vs CP alone (HR 0.44;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3062::c325e03fdbfa80e79ac70dfff118feb4
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/veliparib-with-carboplatin-and-paclitaxel-in-frontline-high-grade-serous-ovarian-cancer-hgsoc-efficacy-and-safety-of-paclitaxel-weekly-and-every
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/veliparib-with-carboplatin-and-paclitaxel-in-frontline-high-grade-serous-ovarian-cancer-hgsoc-efficacy-and-safety-of-paclitaxel-weekly-and-every